Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Alloy Therapeutics

Alloy Therapeutics Selected to Join the World Economic Forum’s Unicorns Community

September 17, 2026

From Alloy Therapeutics

Via Business Wire

Alloy Therapeutics Named a Winner on Fast Company’s 2026 Best Workplaces for Innovators List

September 10, 2026

From Alloy Therapeutics

Via Business Wire

Voro Therapeutics and Alloy Therapeutics Enter Strategic Research Collaboration to Advance Next-Generation Masked T-Cell Engager Therapeutics

June 18, 2026

From Alloy Therapeutics

Via Business Wire

Alloy Therapeutics and Institute for Protein Innovation Announce Strategic Collaboration to Advance Next-Generation Antibody Discovery

May 05, 2026

From Alloy Therapeutics

Via Business Wire

Alloy Therapeutics Appoints Alexander Titus, Ph.D., to Lead New Vigilance Division Focused on Biosecurity and Rapid Therapeutic Response

April 01, 2026

From Alloy Therapeutics

Via Business Wire

Alloy Therapeutics Enters Into Agreement to Advance Novel Antibody Discovery Platform

March 17, 2026

From Alloy Therapeutics

Via Business Wire

Alloy Accelerates Mediar Timeline to the Clinic for Complex Fibrosis Targets

February 03, 2026

From Alloy Therapeutics

Via Business Wire

Tahoe Therapeutics and Alloy Therapeutics to Form Joint Venture and Develop First-in-Class Antibody-Drug Conjugates for Hard-to-Treat Cancers

January 13, 2026

From Alloy Therapeutics

Via Business Wire

Alloy Therapeutics Appoints Christian Cobaugh, Ph.D., as CEO of Alloy Genetic Medicines

January 06, 2026

From Alloy Therapeutics

Via Business Wire

Alloy Therapeutics Establishes Multi-Year Collaboration with Pfizer to Develop New Antibody Discovery Platform

February 11, 2025

From Alloy Therapeutics

Via Business Wire

Alloy Therapeutics Announces New Licensing Model for ATX-Gx™ Antibody Discovery Platform and Launches mAbForge™ High-Throughput Screening Service

January 09, 2025

From Alloy Therapeutics

Via Business Wire

Alloy Therapeutics Announces Institutional License Agreement with Scripps Research for its ATX-Gx™ Platform for Fully Human Antibody Discovery

October 30, 2024

From Alloy Therapeutics

Via Business Wire

Alloy Therapeutics Announces Platform License Agreement with Lilly

May 21, 2024

From Alloy Therapeutics

Via Business Wire

Alloy Therapeutics Announces Scientific Advisory Board to Drive Roadmap of Biotherapeutic Discovery Platform Innovation

September 20, 2023

From Alloy Therapeutics

Via Business Wire

Alloy Therapeutics Expands Executive Team to Strengthen Therapeutic Discovery and Innovation for Its Partners

June 29, 2023

From Alloy Therapeutics

Via Business Wire

Alloy Therapeutics Launches Proprietary AntiClastic™ Antisense Oligonucleotide Platform to Make Potent Genetic Medicines

June 28, 2023

From Alloy Therapeutics

Via Business Wire

Alloy Therapeutics to Empower Drug Discovery of Lundbeck’s Biologics for Brain Health

May 02, 2023

From Alloy Therapeutics

Via Business Wire

Alloy Therapeutics Announces an Expansion of its Antibody Discovery Services in Conjunction with Two New Senior Vice Presidents

April 26, 2023

From Alloy Therapeutics

Via Business Wire

Alloy Therapeutics Unveils 2023 Innovation Roadmap Across Antibodies, TCRs, Bispecifics, and Genetic Medicines

January 09, 2023

From Alloy Therapeutics

Via Business Wire

Alloy Therapeutics and Normunity Sign Multi-Program Antibody Discovery Collaboration in Immuno-Oncology

November 17, 2022

From Alloy Therapeutics

Via Business Wire

Alloy Therapeutics Raises $42 Million Series D Financing to Accelerate Discovery Technology Development Across Biologic Modalities

October 03, 2022

From Alloy Therapeutics

Via Business Wire

Alloy Therapeutics Hires People Executive Trier Bryant as President of Venture Studio, 82VS

September 07, 2022

From Alloy Therapeutics

Via Business Wire

Alloy Therapeutics Ecosystem Offerings Go Intracellular Through Collaboration with Sudhir Agrawal in Genetic Medicines

June 09, 2022

From Alloy Therapeutics

Via Business Wire

Alloy Therapeutics Acquires deepCDR Biologics to Bring Bioinformatics and Machine Learning to its Antibody Discovery Offering

December 09, 2021

From Alloy Therapeutics

Via Business Wire

Alloy Therapeutics and Pyxis Oncology Form Kyma Therapeutics to Develop Novel Immune-Modulating Antibodies for Cancer and Autoimmune Diseases

May 25, 2021

From Alloy Therapeutics

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.